- Home
- CSTL vs GGN Comparison
CSTL vs GGN Comparison
Compare CSTL & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- GGN
- Stock Information
- Founded
- CSTL 2007
- GGN 2005
- Country
- CSTL United States
- GGN United States
- Employees
- CSTL N/A
- GGN N/A
- Industry
- CSTL Medical Specialities
- GGN Finance/Investors Services
- Sector
- CSTL Health Care
- GGN Finance
- Exchange
- CSTL Nasdaq
- GGN Nasdaq
- Market Cap
- CSTL 558.7M
- GGN 648.9M
- IPO Year
- CSTL 2019
- GGN N/A
- Fundamental
- Price
- CSTL $16.75
- GGN $4.17
- Analyst Decision
- CSTL Strong Buy
- GGN
- Analyst Count
- CSTL 6
- GGN 0
- Target Price
- CSTL $38.33
- GGN N/A
- AVG Volume (30 Days)
- CSTL 548.5K
- GGN 397.4K
- Earning Date
- CSTL 05-05-2025
- GGN 01-01-0001
- Dividend Yield
- CSTL N/A
- GGN 10.26%
- EPS Growth
- CSTL N/A
- GGN N/A
- EPS
- CSTL N/A
- GGN N/A
- Revenue
- CSTL $347,083,000.00
- GGN N/A
- Revenue This Year
- CSTL N/A
- GGN N/A
- Revenue Next Year
- CSTL $1.80
- GGN N/A
- P/E Ratio
- CSTL N/A
- GGN N/A
- Revenue Growth
- CSTL 38.43
- GGN N/A
- 52 Week Low
- CSTL $15.70
- GGN $3.51
- 52 Week High
- CSTL $35.84
- GGN $3.91
- Technical
- Relative Strength Index (RSI)
- CSTL 34.74
- GGN 44.56
- Support Level
- CSTL $15.84
- GGN $4.24
- Resistance Level
- CSTL $17.49
- GGN $4.27
- Average True Range (ATR)
- CSTL 0.90
- GGN 0.05
- MACD
- CSTL -0.18
- GGN -0.00
- Stochastic Oscillator
- CSTL 22.73
- GGN 12.41
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About GGN GAMCO Global Gold Natural Resources & Income Trust
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.